-
A hitch in the stitch reveals why DNA sequence patterns matter in Huntington’s disease
Latest News
-
Worms to the Rescue: Separating the Good, the Bad, and the Clumpy Huntingtin
⏱️ 7 min read | A team of researchers developed a simple platform to test how toxic different types of HTT protein clumps are using a laboratory worm model. They showed that certain types of clumps are harmful to the worms, while others are not.
-
Success! ASO drug reduces levels of mutant protein in Huntington's disease patients
Amazing news from Ionis and Roche! HTTRx drug successfully lowers harmful huntingtin protein in spinal fluid
-
Switch off the genome editor when you’re done
CRISPR genome editing just got an off-switch. We cut through the hype to explore the technology in HD
-
A new way of thinking about trials to prevent Huntington's disease
Can we test drugs to delay or prevent the onset of Huntington's disease? New research suggests it's possible
-
New roles for huntingtin: removing a healthy protein to understand its function
Completely removing normal huntingtin in adults may disrupt healthy brain function, a recent study suggests.
-
Precision huntingtin-lowering drug trials target the mutant protein
WAVE Life Sciences launches PRECISION clinical trial to suppress the mutant Huntington's disease protein
-
A step forward for gene editing: CRISPR-Cas9 and HD
Evolving CRISPR-Cas9 techniques can now be used to edit the HD gene in a living mouse brain.
-
Update confirms Huntington's disease 'gene silencing' trial on track
Ionis says its trial of HTTRx, intended to lower huntingtin protein, is fully recruited and plans to extend it
-
New study reveals a potential HD biomarker
A potential HD biomarker has been uncovered in a recent clinical study
-
Has a "wonder drug" for dementia been discovered? (Spoiler alert: no.)
Media reports of a wonder drug for neurodegenerative diseases like Huntington's disease are overhyped
-
Huntington's Disease Therapeutics Conference 2017 – Day 3
HDBuzz summarises final day of the 2017 Huntington's Disease Therapeutics Conference in Malta
HDBuzz Trial Tracker
Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02
Additional insights from Phase 2 study results and update on plans for Phase 3 trial for votoplam
